Summary
The purpose of this study is to provide ongoing access to study treatments for
participants with multiple myeloma or smoldering multiple myeloma benefiting from
treatment in certain Janssen Research and Development (R&D) studies that use daratumumab
as part of the study treatment regimen: access for all participants regardless of
treatment group in daratumumab studies and access to participants in
daratumumab-containing arms in the non-daratumumab studies will be allowed from studies
which have reached clinical cutoff for final analysis. Certain long-term safety data will
continue to be collected from study participants.